Plasma PTX3, MCP1 and Ang2 are early biomarkers to evaluate the severity of sepsis and septic shock

Rui Tian, Xiaoli Wang, Tingting Pan, Ranran Li, Jiahui Wang, Zhaojun Liu, Erzhen Chen, Enqiang Mao, Ruoming Tan, Yang Chen, Jialin Liu, Hongping Qu, Rui Tian, Xiaoli Wang, Tingting Pan, Ranran Li, Jiahui Wang, Zhaojun Liu, Erzhen Chen, Enqiang Mao, Ruoming Tan, Yang Chen, Jialin Liu, Hongping Qu

Abstract

Sepsis is associated with significant mortality. Early diagnosis and prognosis of patients with sepsis is still a difficult clinical challenge. In this study, the ability of plasma PTX3 (pentraxin 3), MCP1 (monocyte chemoattractant protein 1) and Ang (angiopoietin)1/2 was investigated to evaluate the severity of sepsis. Blood samples were obtained from 43 patients with sepsis. A total of 33 post-surgery patients with infections and 25 healthy individuals served as controls. The results showed that plasma PTX3, MCP1 and Ang2 significantly increased in patients on the first day of septic shock onset, while sepsis patients had significantly higher Ang2 level, compared with controls. Furthermore, PTX3, MCP1 and Ang2 had high AUROC values in patients with septic shock on the first day of sepsis onset. The findings suggest that PTX3, MCP1 and Ang2 maybe early predictors to evaluate the severity of sepsis and septic shock with the latest Sepsis 3.0 definitions.

Keywords: Ang2; MCP1; PTX3; pro-inflammatory cytokine; sepsis.

Conflict of interest statement

The authors declare no conflict of interest.

© 2019 The Authors. Scandinavian Journal of Immunology published by John Wiley & Sons Ltd on behalf of The Scandinavian Foundation for Immunology.

Figures

Figure 1
Figure 1
Tian et al Comparative analysis of MCP1, PTX3, Ang1 and Ang2 in patients with sepsis, septic shock, post‐surgery and healthy controls. Concentrations of MCP1, PTX3, Ang1 and Ang2 in plasma from HC (healthy controls, filled circles), sepsis patients (filled squares), septic shock patients (filled triangles) and post‐surgery patients (inversed filled triangles) were measured by Luminex. Data are presented as median (IQR). *P < .05
Figure 2
Figure 2
Tian et al Receiver operating characteristic (ROC) curves for predicting septic shock by plasma level of MCP1, PTX3, Ang1 and Ang2

References

    1. Sagy M, Al‐Qaqaa Y, Kim P. Definitions and pathophysiology of sepsis. Curr Probl Pediatr Adolesc Health Care. 2013;43:260‐263.
    1. Wheeler AP, Bernard GR. Treating patients with severe sepsis. N Engl J Med. 1999;21(340):207‐214.
    1. Koskela M, Ala‐Kokko TI, Gaddnas F, et al. Blister fluid and serum cytokine levels in severe sepsis in humans reflect skin dysfunction. Acta Anaesthesiol Scand. 2017;61:53‐61.
    1. Chousterman BG, Swirski FK, Weber GF. Cytokine storm and sepsis disease pathogenesis. Semin Immunopathol. 2017;39:517‐528.
    1. Yang AP, Liu J, Yue LH, Wang HQ, Yang WJ, Yang GH. Neutrophil CD64 combined with PCT, CRP and WBC improves the sensitivity for the early diagnosis of neonatal sepsis. Clin Chem Lab Med. 2016;54:345‐351.
    1. Silvestre J, Povoa P, Coelho L, et al. Is C‐reactive protein a good prognostic marker in septic patients? Intensive Care Med. 2009;35:909‐913.
    1. O'Grady NP, Barie PS, Bartlett JG, et al. Guidelines for evaluation of new fever in critically ill adult patients: 2008 update from the American college of critical care medicine and the infectious diseases society of America. Crit Care Med. 2008;36:1330‐1349.
    1. Rubino M, Kunderfranco P, Basso G, et al. Epigenetic regulation of the extrinsic oncosuppressor PTX3 gene in inflammation and cancer. Oncoimmunology. 2017;6:e1333215.
    1. Bottazzi B, Doni A, Garlanda C, Mantovani A. An integrated view of humoral innate immunity: pentraxins as a paradigm. Annu Rev Immunol. 2010;28:157‐183.
    1. Bottazzi B, Garlanda C, Cotena A, et al. The long pentraxin PTX3 as a prototypic humoral pattern recognition receptor: interplay with cellular innate immunity. Immunol Rev. 2009;227:9‐18.
    1. Bonavita E, Gentile S, Rubino M, et al. PTX3 is an extrinsic oncosuppressor regulating complement‐dependent inflammation in cancer. Cell. 2015;12(160):700‐714.
    1. Doni A, Garlanda C, Mantovani A. Innate immunity, hemostasis and matrix remodeling: PTX3 as a link. Semin Immunol. 2016;28:570‐577.
    1. Shalova IN, Lim JY, Chittezhath M, et al. Human monocytes undergo functional re‐programming during sepsis mediated by hypoxia‐inducible factor‐1alpha. Immunity. 2015;17(42):484‐498.
    1. Deshmane SL, Kremlev S, Amini S, Sawaya BE. Monocyte chemoattractant protein‐1 (MCP‐1): an overview. J Interferon Cytokine Res. 2009;29:313‐326.
    1. Sorensen TL, Ransohoff RM, Strieter RM, Sellebjerg F. Chemokine CCL2 and chemokine receptor CCR2 in early active multiple sclerosis. Eur J Neurol. 2004;11:445‐449.
    1. Liu Y, Wang W, Zou Z, et al. Monocyte chemoattractant protein 1 released from macrophages induced by hepatitis C virus promotes monocytes migration. Virus Res. 2017;15(240):190‐196.
    1. Matsukawa A, Hogaboam CM, Lukacs NW, Lincoln PM, Strieter RM, Kunkel SL. Endogenous MCP‐1 influences systemic cytokine balance in a murine model of acute septic peritonitis. Exp Mol Pathol. 2000;68:77‐84.
    1. Leligdowicz A, Richard‐Greenblatt M, Wright J, Crowley VM, Kain KC. Endothelial activation: the Ang/Tie Axis in sepsis. Front Immunol. 2018;9:838.
    1. Saharinen P, Eklund L, Alitalo K. Therapeutic targeting of the angiopoietin‐TIE pathway. Nat Rev Drug Discov. 2017;16:635‐661.
    1. Fiedler U, Scharpfenecker M, Koidl S, et al. The Tie‐2 ligand angiopoietin‐2 is stored in and rapidly released upon stimulation from endothelial cell Weibel‐Palade bodies. Blood. 2004;1(103):4150‐4156.
    1. Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (Sepsis‐3). JAMA. 2016;23(315):801‐810.
    1. Muller B, Peri G, Doni A, et al. Circulating levels of the long pentraxin PTX3 correlate with severity of infection in critically ill patients. Crit Care Med. 2001;29:1404‐1407.
    1. Han B, Mura M, Andrade CF, et al. TNFalpha‐induced long pentraxin PTX3 expression in human lung epithelial cells via JNK. J Immunol. 2005;15(175):8303‐8311.
    1. He X, Han B, Bai X, et al. PTX3 as a potential biomarker of acute lung injury: supporting evidence from animal experimentation. Intensive Care Med. 2010;36:356‐364.
    1. Dias AA, Goodman AR, Dos Santos JL, et al. TSG‐14 transgenic mice have improved survival to endotoxemia and to CLP‐induced sepsis. J Leukoc Biol. 2001;69:928‐936.
    1. Hamed S, Behnes M, Pauly D, et al. Diagnostic value of Pentraxin‐3 in patients with sepsis and septic shock in accordance with latest sepsis‐3 definitions. BMC Infect Dis. 2017;9(17):554.
    1. Fornai F, Carrizzo A, Forte M, et al. The inflammatory protein Pentraxin 3 in cardiovascular disease. Immun Ageing. 2016;13:25.
    1. Slusher AL, Mischo AB, Acevedo EO. Pentraxin 3 is an anti‐inflammatory protein associated with lipid‐induced interleukin 10 in vitro. Cytokine. 2016;86:36‐40.
    1. Caironi P, Masson S, Mauri T, et al. Pentraxin 3 in patients with severe sepsis or shock: the ALBIOS trial. Eur J Clin Invest. 2017;47:73‐83.
    1. Gesta S, Guntur K, Majumdar ID, et al. Reduced expression of collagen VI alpha 3 (COL6A3) confers resistance to inflammation‐induced MCP1 expression in adipocytes. Obesity (Silver Spring). 2016;24:1695‐1703.
    1. Xie Z, Wang P, Li J, et al. MCP1 triggers monocyte dysfunctions during abnormal osteogenic differentiation of mesenchymal stem cells in ankylosing spondylitis. J Mol Med (Berl). 2017;95:143‐154.
    1. Lee CC, Ho HC, Su YC, Lee MS, Hung SK, Lin CH. MCP1‐induced epithelial‐mesenchymal transition in head and neck cancer by AKT activation. Anticancer Res. 2015;35:3299‐3306.
    1. Zhu T, Liao X, Feng T, et al. Plasma monocyte chemoattractant protein 1 as a predictive marker for sepsis prognosis: a prospective cohort study. Tohoku J Exp Med. 2017;241:139‐147.
    1. Barre M, Behnes M, Hamed S, et al. Revisiting the prognostic value of monocyte chemotactic protein 1 and interleukin‐6 in the sepsis‐3 era. J Crit Care. 2018;43:21‐28.
    1. Wang Y, Liu Q, Liu T, et al. Early plasma monocyte chemoattractant protein 1 predicts the development of sepsis in trauma patients: a prospective observational study. Medicine (Baltimore). 2018;97:e0356.
    1. Isidori AM, Venneri MA, Fiore D. Angiopoietin‐1 and Angiopoietin‐2 in metabolic disorders: therapeutic strategies to restore the highs and lows of angiogenesis in diabetes. J Endocrinol Invest. 2016;39:1235‐1246.
    1. de Jong GM, Slager JJ, Verbon A, van Hellemond JJ, van Genderen PJ. Systematic review of the role of angiopoietin‐1 and angiopoietin‐2 in Plasmodium species infections: biomarkers or therapeutic targets? Malar J. 2016;1(15):581.
    1. Xing LY, Yin J, Shao M, et al. Clinical characteristics and prognosis of serous body cavity effusions in patients with sepsis: a retrospective observational study. BMC Anesthesiol. 2018;14(18):169.
    1. Scholz A, Plate KH, Reiss Y. Angiopoietin‐2: a multifaceted cytokine that functions in both angiogenesis and inflammation. Ann N Y Acad Sci. 2015;1347:45‐51.
    1. Roviezzo F, Tsigkos S, Kotanidou A, et al. Angiopoietin‐2 causes inflammation in vivo by promoting vascular leakage. J Pharmacol Exp Ther. 2005;314:738‐744.
    1. David S, Park JK, Meurs M, et al. Acute administration of recombinant Angiopoietin‐1 ameliorates multiple‐organ dysfunction syndrome and improves survival in murine sepsis. Cytokine. 2011;55:251‐259.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren